Differential effects of commercial-grade and purified poloxamer 188 on renal function

Drugs in R and D

Volumn 14, Issue 2, 2014, Pages 73-83

  Emanuele, Martin ^a   Balasubramaniam, Balu ^a  

^a Mast Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; P 188NF; POLOXAMER; UNCLASSIFIED DRUG; VEPOLOXAMER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HISTOLOGY; KIDNEY DISEASE; KIDNEY FUNCTION; LOADING DRUG DOSE; MOLECULAR WEIGHT; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PURIFICATION; RAT; SICKLE CELL ANEMIA; ULTRASTRUCTURE; ADOLESCENT; ANIMAL; CHEMICALLY INDUCED; CHILD; DISEASE MODEL; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; PATHOLOGY; SPRAGUE DAWLEY RAT; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANIMALS; CHILD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY DISEASES; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 84904365463     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0041-0     Document Type: Article

References (42)

1. Moloughney JG, Weisleder N. Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications. Recent Pat Biotechnol. 2012;6(3):200-11.
2. Maskaarinec S, Wu G, Lee K. Membrane sealing by poloxamers. Ann N.Y. Acad Sci. 1066;2005:310-20.
3. Marks JD, Pan CY, Bushell T, Cromie W, Lee RC. Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection. FASEB J. 2001;15(6):1107-9.
4. Manno S, Takakuwa Y, et al. Identification of a functional role for lipid asymmetry in biological membranes: phosphatidylserine-skeletal protein interactions modulate membrane stability. Proc Natl Acad Sci USA. 2002;99(4):1943-8. (Pubitemid 34168994)
5. 2+-induced scrambling of phosphatidylserine. Mol Membr Biol. 2003;20(1):83-91.
6. Curry D, Wright D, Lee R, Kang U, Frim D. J. Neurosurg. 2004;101:(1 Suppl) 91-6.
7. Hunter R, Luo A, Zhang R, Kozar r, Moore F. Poloxamer 188 inhibition of ischemia reperfusion injury: evidence for a novel anti-adhesion mechanism. Ann Clin Lab Sci. 2010;40:(2)115.
8. Unpublished data, Mast therapeutics.
9. Barwal I, Sood A, Sharma M, Singh B, Yadav SC. Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf B Biointerfaces. 2013;1(101):510-6.
10. Zhang B, Mallapragada S. The mechanism of selective transfection mediated by pentablock copolymers; part II: nuclear entry and endosomal escape. Acta Biomater. 2011;7(4):1580-7.
11. Yasuda A, Townsend D, Michele D, Favre E, Day S, Metzger J. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:(18)1025- 1029. (Pubitemid 41191686)
12. Juneman E, Saleh L, Lancaster J, Thai H, Markhan B, Goldman S. The effects of poloxamer 188 on left ventricular function in chronic heart failure after myocardial infaction. J Cardiovasc Pharmacol. 2012;60:(3)293-8.
13. Baskaran H, Toner M, Yarmush M, Berthiaume F. Poloxamer 188 improves capillary blood flow and tissue viability in a cutaneous burn wound. J Surg Res. 2001;101(1):56-61. (Pubitemid 33030107)
14. Murphy A, McCormack M, Bichara B, Randolf W, Austen W. Poloxamer 188 significantly decreases muscle necrosis in a murine hindlimb model of ischemia reperfusion injury. J Surg Res. 2009;151(2):220-1.
15. Hunter RL, Papadea C, Gallagher CJ, Finlayson DC, Check IJ. Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188. Thromb Haemost. 1990;63(1):6-12. (Pubitemid 20057304)
16. Grover FL, Kahn RS, Heron MW, Paton BC. A nonionic surfactant and blood viscosity. Experimental observations. Arch Surg. 1973;106(3):307-10.
17. Gaehtgens P, Benner KU. Desaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and hemolysis. Acta Haematol. 1975;53(2):82-9.
18. Carter C, Fisher TC, Hamai H, Johnson CS, Meiselman HE, Nah GB, Stuart J. Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorheol. 1992;12:109-20.
19. Hunter RL, Bennett B, Check IJ. The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase. Fibrinolysis. 1990;4:117-23. (Pubitemid 20270737)
20. Carr ME Jr, Powers PL, Jones MR. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb Haemost. 1991;66(5):565-8.
21. Justicz A, Farnsworth W, Soberman M, Tuvlin G, Bonner R, Hunter R, Martino-Saltzman D, Sink J, Austin G. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am Heart J. 1991;122:671-80.
22. Schaer GL, Hursey TL, Abrahams SL, Buddemeier K, Ennis B, Rodriguez ER, Hubbell JP, Moy J, Parrillo JE. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188, N.F.), a hemorheological agent that alters neutrophil function. Circulation. 1994;90:2964-75.
23. Robinson KA, Hunter RL, Stack JE, Hearn JA, Apkarian RP, Roubin GS. Inhibition of coronary arterial thrombosis in swine by infusion of poloxamer 188. J Invas Cardiol. 1990;2:9-20.
24. O'Keefe JH, Grines CL, DeWood MA, Schaer GL, Browne K, Magorien RD, Kalbfleisch JM, Fletcher WO Jr, Bateman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;78(7):747-50. (Pubitemid 126657142)
25. Burns J, Baer L, Jones J, Dubick M, Wade C. Severe controlled hemorrhage resuscitation with small volume poloxamer 188 in sedated miniature swine. Resuscitation. 2011;82(11):1453-9.
26. Zhang R, Hunter RL, Gonzalez EA, Moore FA. Poloxamer 188 prolongs survival of hypotensive resuscitation and decreases vital tissue injury after full resuscitation. Shock. 2009;32(4):442-50.
27. Gu JH, Ge JB, Li M, Xu HD, Wu F, Qin ZH. Poloxamer 188 protects neurons against ischemia/reperfusion injury through preserving integrity of cell membranes and blood brain barrier. PLoS One. 2013;8(4):e61641.
28. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Weith K, Ward D, Crawford R, Edwards S, Bustrack J, Emanuele M. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90(5):2041-8.
29. Orringer E, Casella J, Ataga K, Koshy M, Adams-Graves P, Luchman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Aboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz S, Grindel M. Purified Poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease. JAMA 2001;286(17):2099-106. (Pubitemid 34041594)
30. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation. 1996;94(3):298-307. (Pubitemid 26266112)
31. Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE). Circulation. 1997;96(1):192-201.
32. Smith S, Anderson S, Ballermann BJ, Brenner BM. Role of atrial natriuretic peptide in adaptation of sodium excretion with reduced renal mass. J Clin Invest. 1986;77(4):1395-8. (Pubitemid 16047166)
33. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4(12):2023-31. (Pubitemid 24977009)
34. Ibrahim HN, Hostetter TH. The renin-aldosterone axis in two models of reduced renal mass in the rat. J Am Soc Nephrol. 1998;9(1):72-6. (Pubitemid 28050046)
35. Heinegård D, Tiderström G. Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta. 1973;43(3):305-10.
36. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 http://ctep.cancer.gov. Publish Date: 9 Aug 2006.
37. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubule vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci. 1998;42(2):152-7. (Pubitemid 28211143)
38. Rudmann DG, Alston JT, Hanson JC, Heidel S. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol. 2013;41(7):970-83.
39. Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 2012;14(9):20.
40. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med. 1994;154(17):1985-7. (Pubitemid 24276385)
41. Schmolka IR. Polyalkylene oxide block copolymers. In: Shick MJ, editor. Nonionic surfactants, vol 1. New York: Macrel Dekker; 1966. p. 30-7.
42. Maskarinec SA, Wu G, Lee KY. Membrane sealing by polymers. Ann NY Acad Sci. 2005;1066:310-20.